Preda Marius, Ilina Răzvan, Potre Ovidiu, Potre Cristina, Mazilu Octavian
1st Department of Surgery, Discipline of Surgical Semiology II, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
2nd General and Oncological Surgery Clinic, Timisoara's Emergency City Hospital, Timisoara, Romania.
Cancer Manag Res. 2020 Dec 3;12:12447-12455. doi: 10.2147/CMAR.S278795. eCollection 2020.
To evaluate the survival of patients with inflammatory breast cancer (IBC) and to correlate these survival rates with the histopathological parameters found in the resection specimen of the tumor.
This retrospective study was based on 27 patients that had been diagnosed and had undergone surgery in the 2nd General and Oncological Surgery Clinic of the County Emergency Hospital in Timisoara, Romania. Data about the patient group were collected from archived patient files over a period of eight years starting from January 2008. The collected data regarded age, tumor size and histopathological type and immunohistochemistry (IHC), presence or absence of tumor embolus in lymphatic or blood vessels and the presence or absence of distant metastases at the time of diagnosis. We evaluated the impact of tumor characteristics on the patients' outcome.
The 12-month survival rates postsurgery were significantly increased if tumors were <5 cm compared to those >5 cm (=0.046), if nodal status was N0 vs N1-2 (=0.039), as well as in cases where distant metastases were absent, compared to patients with distant metastases (=0.001, α=0.001) and positive-hormone receptors (=0.043). Survival was influenced neither by histopathological type (=0.357) nor by the presence of tumor embolus in the resection specimen (=0.250) and HER2 status (=0.763). Survival at 12 months after surgery was equal between those with stage IIIB noninflammatory breast cancer (NIBC) and IBC. At 24 months after surgery, IBC cases presented a significantly lower probability of survival.
The prognosis of patients with IBC is reserved compared to NIBC, increased tumor size, positive lymph node, hormone receptors negative cases and distant metastases drastically decreasing survival rates.
评估炎性乳腺癌（IBC）患者的生存率，并将这些生存率与肿瘤切除标本中发现的组织病理学参数相关联。
这项回顾性研究基于罗马尼亚蒂米什瓦拉县急诊医院第二普通与肿瘤外科诊所诊断并接受手术的27例患者。从2008年1月开始的八年时间里，从存档的患者病历中收集了有关患者组的数据。收集的数据包括年龄、肿瘤大小、组织病理学类型和免疫组化（IHC）、淋巴管或血管中是否存在肿瘤栓子以及诊断时是否存在远处转移。我们评估了肿瘤特征对患者预后的影响。
与肿瘤直径>5 cm的患者相比，肿瘤直径<5 cm的患者术后12个月生存率显著提高（P=0.046）；淋巴结状态为N0的患者与N1-2的患者相比，术后12个月生存率显著提高（P=0.039）；与有远处转移的患者相比，无远处转移的患者术后12个月生存率显著提高（P=0.001，α=0.001），激素受体阳性的患者术后12个月生存率显著提高（P=0.043）。生存率不受组织病理学类型（P=0.357）、切除标本中是否存在肿瘤栓子（P=0.250）及HER2状态（P=0.763）的影响。IIIB期非炎性乳腺癌（NIBC）患者和IBC患者术后12个月的生存率相等。术后24个月，IBC患者的生存概率显著降低。
与NIBC相比，IBC患者的预后较差，肿瘤大小增加、淋巴结阳性、激素受体阴性及远处转移会显著降低生存率。
